Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.60 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28403784 | 0.90 | DRD2 (0.63) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL29756191 | 0.90 | DRD2 (0.63) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL28951004 | 0.89 | KDM4E (0.59) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL4718616 | 0.85 | KDM4E (0.63) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL19969998 | 0.83 | DRD2 (0.52) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL4525557 | 0.83 | PDE3B (0.56) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL27572419 | 0.83 | DRD2 (0.72) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL31504073 | 0.82 | PARP10 (0.64) | KDM4EMAPTMEN1NPC1KMT2A | |
| SCHEMBL31504071 | 0.82 | PARP10 (0.64) | KDM4EMAPTMEN1NPC1KMT2A | |
| Biphenyl SCHEMBL27484440 | 0.82 | NPC1 (0.48) | KDM4EMAPTMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107868089-B | A kind of synthetic method of 5,12- dihydro -5- Phenylindole simultaneously [3,2-a] carbazole | 河南省科学院化学研究所有限公司 | 2019-08-27 | — | — | CN | claimed |
| CN-107868089-A | A kind of synthetic method of the Phenylindole of 5,12 dihydro 5 simultaneously [3,2 a] carbazole | 河南省科学院化学研究所有限公司 | 2018-04-03 | — | — | CN | claimed |
| CN-119822910-A | Method for catalyzing heterogeneous reduction of nitrogen-containing heterocyclic compound by using magnesium metal | 延安大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| CN-111747970-B | Containing SO2Polyheterocyclic compounds and their use | 北京燕化集联光电技术有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2021061053-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-04-01 | — | — | WO | disclosed |
| CN-111747970-A | Containing SO2Polyheterocyclic compounds and their use | 北京燕化集联光电技术有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| CN-1129937-A | Indoline derivatives as 5HT2C antagonists | SMITHKLINE BEECHAM PLC (GB) | 1996-08-28 | — | — | CN | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | USP30, USP1, USP20 | KDM4E 508/4885MAPT 2689/4885MEN1 3103/4885 |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | USP30, USP1, USP20 | KDM4E 508/4885MAPT 2689/4885MEN1 3103/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | KDM4E 1503/4885MAPT 4020/4885MEN1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.